Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Mar 30:2022:6552781.
doi: 10.1155/2022/6552781. eCollection 2022.

Association of Blood Amyloid Beta-Protein 1-42 with Poststroke Cognitive Impairment: A Systematic Review and Meta-Analysis

Hui Chen  1 , Sichun Gu  2 , Xiaoying Liu  1 , Anjie Xie  1 , Changde Wang  1
Affiliations
Meta-Analysis

Association of Blood Amyloid Beta-Protein 1-42 with Poststroke Cognitive Impairment: A Systematic Review and Meta-Analysis

Hui Chen et al. Biomed Res Int. .

Abstract

Background: Increases in blood of amyloid beta-protein (Aβ) have been noted in patients with Alzheimer's dementia (AD). Recent studies have shown that blood amyloid beta-protein 1-42 (Aβ1-42) level is closely related to poststroke cognitive impairment (PSCI), which may be the influencing factor and even a predictor of PSCI. The aim of this systematic review was to synthesize the evidence for the association of cognitive impairment among PSCI.

Methods: PubMed (MEDLINE), EMBASE, Cochrane Library, the Cochrane Central Register of Controlled Trial (CENTRAL), CNKI, and WanFang data were searched. Case-control, cohort, and cross-sectional studies that evaluated the association between blood Aβ1-42 and PSCI were included irrespective of language and date of publication. The outcomes of this review consisted of (1) any dementia, (2) any cognitive impairment, and (3) any cognitive impairment no dementia, which were assessed at least 3 months (90 days) after stroke. Exposure of interest was blood Aβ1-42 level (including serum and plasma).

Results: Of 617 records retrieved, 8 studies (6 case-control and 2 cohort studies) involving 931 stroke patients were included for further analysis. 8 studies with 931 subjects explored the correlation between Aβ1-42 and PSCI. PSCI was reported in 457 patients, and the pooled SMD of amyloid beta-protein 1-42 was -0.96 (95% CI -1.10~-0.82, I 2 = 15%, P < 0.01). The results remained robust in sensitivity analysis adjusting for study quality, sample source, and cognitive scale score in analysis of studies, as well as in analysis adjusted for publication bias.

Conclusions: Blood Aβ1-42 level was significantly negatively related to the risk for PSCI, and more prospective studies with large sample size are needed to define a precise threshold value of blood Aβ1-42 level to predict PSCI in the future. This study is registered with PROSPERO, registration number: CRD42021246165.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicting interests.

Figures

Figure 1
Figure 1
Flowchart of the study collection for the present review and meta-analysis.
Figure 2
Figure 2
Studies on the association of blood Aβ1-42 level with PSCI.
Figure 3
Figure 3
Funnel plot of the association of blood amyloid beta-protein (1-42) level in PSCI group and control group.
Figure 4
Figure 4
Egger's test for the association of blood amyloid beta-protein (1-42) level in PSCI group and control group.
Figure 5
Figure 5
Sensitivity analysis for the association of blood amyloid beta-protein 1-42 level in PSCI group and control group.
See this image and copyright information in PMC

References

    1. Kuzma E. K., Boucher N., Gray B., Burmester K., Ploutz-Snyder R., Strobbe S. Preparing advanced practice registered nursing students to deliver adolescent sbirt for substance use. The Journal of Nursing Education . 2018;57(12):736–741. doi: 10.3928/01484834-20181119-06. - DOI - PubMed
    1. Savva G. M., Stephan B. C., the Alzheimer’s Society Vascular Dementia Systematic Review Group Epidemiological studies of the effect of stroke on incident dementia: a systematic review. Stroke . 2010;41(1):e41–e46. doi: 10.1161/STROKEAHA.109.559880. - DOI - PubMed
    1. Pendlebury D. F., Fujiwara Y., Tesmer V. M., et al. Dissecting the telomere-inner nuclear membrane interface formed in meiosis. Nature Structural & Molecular Biology . 2017;24(12):1064–1072. doi: 10.1038/nsmb.3493. - DOI - PMC - PubMed
    1. Kulesh A. A., Shestakov V. V. Post-stroke cognitive impairment and the possibility of treatment with cellex. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova . 2016;116(5):38–42. doi: 10.17116/jnevro20161165138-42. - DOI - PubMed
    1. Molad J., Hallevi H., Korczyn A. D., et al. Vascular and neurodegenerative markers for the prediction of post-stroke cognitive impairment: results from the TABASCO study. Journal of Alzheimer's Disease . 2019;70(3):889–898. doi: 10.3233/JAD-190339. - DOI - PubMed